ANRO
Alto Neuroscience, Inc.
NYSE · Healthcare · Biotechnology · US
$22.82
+4.01%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.67
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.65
- EPS estimate
- -$0.73
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +1.3%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $41
- PT range
- $26 – $60
- Analysts
- 3
2 Buy1 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.73 | -$0.65 | Beat 11.51% | — |
| May 13, 2026 | -$0.56 | -$0.80 | Miss -42.86% | — |
| Mar 16, 2026 | -$0.53 | -$0.45 | Beat 15.30% | — |
| Nov 12, 2025 | -$0.66 | -$0.52 | Beat 21.21% | — |
| Aug 13, 2025 | -$0.57 | -$0.65 | Miss -14.04% | — |
| May 14, 2025 | -$0.59 | -$0.53 | Beat 10.17% | — |
| Mar 20, 2025 | -$0.65 | -$0.56 | Beat 13.85% | — |
| Aug 13, 2024 | -$0.71 | -$0.60 | Beat 15.49% | — |
| Mar 21, 2024 | -$1.67 | -$7.77 | Miss -365.27% | $372.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026